$0.2998
At close: Mar 13, 10:26 AM EDT
Comments
Loading...
Zelira Therapeutics Analyst Ratings and Price Targets | OTC:ZLDAF | Benzinga
Zelira Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Zelira Therapeutics Corp from these most-recent analyst ratings.
Analyst Ratings for Zelira Therapeutics
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Zelira Therapeutics (ZLDAF) stock?
There is no price target for Zelira Therapeutics
What is the most recent analyst rating for Zelira Therapeutics (ZLDAF)?
There is no analyst for Zelira Therapeutics
When was the last upgrade for Zelira Therapeutics (ZLDAF)?
There is no last upgrade for Zelira Therapeutics
When was the last downgrade for Zelira Therapeutics (ZLDAF)?
There is no last downgrade for Zelira Therapeutics.
When is the next analyst rating going to be posted or updated for Zelira Therapeutics (ZLDAF)?
There is no next analyst rating for Zelira Therapeutics.
Is the Analyst Rating Zelira Therapeutics (ZLDAF) correct?
There is no next analyst rating for Zelira Therapeutics.
Browse analyst ratings and price targets on all stocks.